Archives of Medical Research
Volume 35, Issue 6 , Pages 499-506 , November 2004

Effects of long-term administration of nicotine and fluoxetine on sleep in depressed patients

  • Reyes Haro

      Affiliations

    • Clínica de Trastornos de Sueño, Facultad de Medicina
    • ,
  • René Drucker-Colín

      Affiliations

    • Clínica de Trastornos de Sueño, Facultad de Medicina
    • Departamento de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, Mexico
    • Corresponding Author InformationAddress reprint requests to: Dr. René Drucker-Colín, Depto. de Neurociencias, Instituto de Fisiología Celular, Apdo. Postal 70-600, Universidad Nacional Autónoma de México, 04510 México, D.F., México. Telephone: (52-55) 5550-6662. Fax: (52-55) 5550-0904

Received 24 May 2004 ,Accepted 26 August 2004.

References 

  1. Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry. 1992;49:651–668
  2. Rush AJ, Erman MK, Giles DE, Schlesser MA, Carpenter G, Vasavada K, et al. Polysomnographic findings in recently drug-free and clinically remitted depressed patients. Arch Gen Psychiatry. 1986;43:878–884
  3. Armitage R. Effects of antidepressant treatment on sleep EEG in depression. J Psychopharmacol. 1996;1(S10):22–25
  4. Buysse DJ, Hall M, Begley A, Cherry CR, Houck PR, Land S, et al. Sleep and treatment response in depression: new findings using power spectral analysis. Psychiatry Res. 2001;103:51–67
  5. Brunello N, Armitage R, Feinberg I, Holsboer-Trachsler E, Léger D, Linkowski P, et al. Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment. Neuropsychobiology. 2000;42:107–119
  6. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60(S17):28–31
  7. Giles DE, Jarrett RB, Roffwarg HP, Rush AJ. Reduced rapid eye movement latency. A predictor of recurrence in depression. Neuropsychopharmacology. 1987;1:51–59
  8. Heiligenstein JH, Faries DE, Rush AJ, Andersen JS, Pande AC, Roffwarg HP, et al. Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. Psychiatry Res. 1994;10:85–91
  9. Sandor P, Shapiro CM. Sleep patterns in depression and anxiety: theory and pharmacological effects. J Psychosom Res. 1994;38(S1):125–139
  10. Van den Hoofdakker RH, Beersma DGM. On the contribution of sleep wake physiology to the explanation and the treatment of depression. Acta Psychiat Scand. 1988;S341:53–71
  11. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol. 1987;7:24S
  12. Nicholson AN, Pascoe PA. Studies on the modulation on the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacology. 1988;27(6):597–602
  13. Yatham LN, Liddle PF, Shiah IS, Scarrow G, Lam RW, Adam MJ, et al. Brain serotonin2 receptors in major depression. Arch Gen Psychiatry. 2000;57:850–858
  14. Velázquez-Moctezuma J, Shalauta MD, Gillin JC, Shiromani PJ. Microinjections of nicotine in the medial pontine reticular formation elicits REM sleep. Neurosci Lett. 1990;115:265–268
  15. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry. 1997;58(5):185–192
  16. Armitage R, Yonkers K, Cole D, Rush AJ. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol. 1997;17(3):161–168
  17. Vogel GW, Buffenstein A, Minter K, Hennessey A. Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev. 1990;14:49–63
  18. Armitage R, Trivedi M, Rush AJ. Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology. 1995;12(2):159–165
  19. Ciapparelli A, Dani A, Figura A, Gemignani A, Guazzelli M. The effects of fluoxetine on sleep pattern: a clinical and all-night EEG study in patients with major depression. J Sleep Res. 1992;1:41
  20. Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology. 1996;14:437–442
  21. Hendrickse WA, Roffwarg HP, Grannemann BD, Orsulak PJ, Armitage R, Cain JW, et al. The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. Neuropsychopharmacology. 1994;10(2):85–91
  22. Kerkhofs M, Rielaert C, de Maertelaer V, Linkowski P, Czarka M, Mendlewicz J. Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables. Int Clin Psychopharmacol. 1990;5:252–260
  23. Trivedi MH, Rush AJ, Armitage R, Gullion CD, Grannemann BD, Orsulak PJ, et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology. 1999;20(5):447–459
  24. Gillin JC, Lardon M, Ruiz C, Golshan S, Salín-Pascual RJ. Dose-dependent effects of transdermal nicotine on early morning awakening and rapid eye movement sleep time in nonsmoking normal volunteers. J Psychopharmacol. 1994;14:264–267
  25. Salín-Pascual RJ, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 1998;9:57–60
  26. Thorsteinsson HS, Gillin JC, Patten CA, Golshan S, Sutton LD, Drummond S, et al. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology. 2001;24:350–358
  27. Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiological study of young adults. Am J Psychiatry. 1992;149:464–469
  28. Salín-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Colín R. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology. 1995;121:476–479
  29. Pomerleau CS, Pomerleau OF. Euphoriant effects of nicotine in smokers. Psychopharmacology. 1992;108:460–465
  30. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Los Angeles, CA: UCLA Brain Information Service/Brain Research Institute; 1968;
  31. Rioux P, Kibleur Y, Frachon O, von Frenckell R, Zariflan R. A double-blind comparison of nefazodone and fluoxetine in depressed patients. Am J Psychiatry. 1996;153:164
  32. Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry. 1998;44:3–14
  33. Mihailescu S, Drucker-Colín R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000;31:131–144
  34. Mihailescu S, Guzmán-Marín R, Drucker-Colín R. Nicotine stimulation of dorsal raphe neurons: effects on laterodorsal and pedunculopontine neurons. Eur Neuropsychopharmacol. 2001;11:359–366
  35. Vázquez J, Guzmán-Marín R, Salín-Pascual RJ, Drucker-Colín R. Transdermal nicotine on sleep and PGO spikes. Brain Res. 1996;737:317–320
  36. Mihailescu S, Palomero-Rivero P, Meade-Huerta A, Maza-Flores R, Drucker-Colin R. Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol. 1998;360:31–36
  37. Knowles JB, MacLean AW, Cairns J. Definitions of REM latency: some comparisons with particular reference to depression. Biol Psychiatry. 1982;17(9):993–1002
  38. Coble P, Kupfer DJ, Shaw DH. Distribution of REM latency in depression. Biol Psychiatry. 1981;16:453–466
  39. Marks MJ, Burch JB, Collins AC. Effects of chronic nicotine infusion on tolerance development and cholinergic receptors. J Pharmacol Excerpt Ther. 1983;226:806–816
  40. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgemeyer I, Heinemann F, et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci. 1992;12(7):2765–2784
  41. Guzmán-Marín R, Alam N, Mihailescu S, Szymusiak R, McGinty D, Drucker-Colin R. Subcutaneous administration of nicotine changes dorsal raphe serotonergic neurons discharge rate during REM sleep. Brain Res. 2001;888:321–325
  42. Keck PE, Hudson JI, Dorsey DM, Campbell PI. Effects of fluoxetine on sleep. Biol Psychiatry. 1991;29:618–619
  43. Saletu B, Frey R, Krupka M, Anderer P, Grünberger J, See WR. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep. 1991;14(5):439–447
  44. Saletu B, Grünberger J. Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetics, pharmaco-EEG and psychometric analyses. J Clin Psychiatry. 1985;46:45–52
  45. von Bardeleben U, Steiger A, Gerken A, Holsboer F. Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. Int Clin Psychopharmacol. 1989;4(S1):1–5
  46. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiological disposition. J Clin Psychiatry. 1985;46:14–19
  47. Stark P, Fuller RW, Wong DT. The pharmacologic profile of fluoxetine. J Clin Psychiatry. 1985;46:7–13
  48. Winkler D, Tauscher J, Kasper S. Maintenance treatment in depression: the role of pharmacological and psychological treatment. Curr Opin Psychiatry. 2002;15:63–68
  49. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C] DASB PET imaging study. Am J Psychiatry. 2001;158:1843–1849

PII: S0188-4409(04)00141-9

doi: 10.1016/j.arcmed.2004.11.010

Archives of Medical Research
Volume 35, Issue 6 , Pages 499-506 , November 2004

Article Tools

* Image Usage & Resolution